Gilead Sciences has announced licensing deals with five India- and Pakistan-based generics firms that will allow them to manufacture remdesivir for distribution in 127 countries across the globe.
A week ago, Gilead had revealed that it was in discussions with firms over licensing deals for the investigational antiviral, which is a potential treatment for COVID-19, as well as having “active discussions” with the Medicines Patent Pool to license remdesivir for developing countries